Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) EBT Margin (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EBT Margin for 8 consecutive years, with 2030.75% as the latest value for Q2 2025.

  • Quarterly EBT Margin changed N/A to 2030.75% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 12967.17% through Dec 2025, changed N/A year-over-year, with the annual reading at 1401.16% for FY2025, N/A changed from the prior year.
  • EBT Margin for Q2 2025 was 2030.75% at Crescent Biopharma, up from 17690.09% in the prior quarter.
  • The five-year high for EBT Margin was 2030.75% in Q2 2025, with the low at 10140324.65% in Q2 2021.
  • Average EBT Margin over 3 years is 1712701.16%, with a median of 18856.78% recorded in 2021.
  • The sharpest move saw EBT Margin plummeted -8929557bps in 2021, then surged 1012263456bps in 2022.
  • Over 3 years, EBT Margin stood at 98847.07% in 2021, then skyrocketed by 82bps to 17690.09% in 2022, then skyrocketed by 111bps to 2030.75% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 2030.75%, 17690.09%, and 98847.07% for Q2 2025, Q2 2022, and Q4 2021 respectively.